PDE5A inhibition, which boosts NO-cGMP signaling, will relieve functional muscle ischemia and
restore normal blood flow regulation (i.e., functional sympatholysis) during exercise in boys
with DMD. The investigators specific aim is to perform an efficient dose-titration study to
inform the design of a randomized multicenter trial of PDE5A inhibition for clinical skeletal
muscle and cardiac endpoints.